ETOPOSID Sandoz 20 mg/1 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

etoposid sandoz 20 mg/1 ml koncentrat za rastvor za infuziju

sandoz d.o.o. - etopozid - koncentrat za rastvor za infuziju - 20 mg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži: 20 mg etopozida

Etoposide Sandoz 20 mg/ml koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

etoposide sandoz 20 mg/ml koncentrat za otopinu za infuziju

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - etopozid - koncentrat za otopinu za infuziju - 20 mg/ml - urbroj: 1 ml koncentrata za otopinu za infuziju sadrži 20 mg etopozida

Imfinzi Europska Unija - hrvatski - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Etopozid Cipla 20 mg/ml koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

etopozid cipla 20 mg/ml koncentrat za otopinu za infuziju

cipla (eu) limited, hillbrow house, hillbrow road, esher, surrey, velika britanija - etoposidum - koncentrat za otopinu za infuziju - 20 mg/ml - urbroj: 1 ml koncentrata za otopinu za infuziju sadrži 20 mg etopozida

Tecentriq Europska Unija - hrvatski - EMA (European Medicines Agency)

tecentriq

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

ZYTRON 8 mg/4 mL rastvor za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zytron 8 mg/4 ml rastvor za injekciju

alkaloid d.o.o. sarajevo - ондансетрон - rastvor za injekciju - 8 mg/4 ml - 4 ml rastvora za injekciju sadrži: 8 mg ondansetrona (u obliku ondansetronhidrohlorid, dihidrata)

ZYTRON 4 mg/2 mL rastvor za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zytron 4 mg/2 ml rastvor za injekciju

alkaloid d.o.o. sarajevo - ондансетрон - rastvor za injekciju - 4 mg/2 ml - 2 ml rastvora za injekciju sadrži: 4 mg ondansetrona (u obliku ondansetronhidrohlorid, dihidrata)

Karmustin Teva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

karmustin teva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju

teva b.v., swensweg 5, haarlem, nizozemska - karmustin - prašak i otapalo za koncentrat za otopinu za infuziju - 100 mg - urbroj: jedna bočica praška sadrži 100 mg karmustina

Cisplatin Pliva 0,5 mg/ml koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

cisplatin pliva 0,5 mg/ml koncentrat za otopinu za infuziju

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - cisplatin - koncentrat za otopinu za infuziju - 0,5 mg/ml - urbroj: 1 ml koncentrata sadrži 0,5 mg cisplatina

GEMCITABIN Ebewe 10 mg/1 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gemcitabin ebewe 10 mg/1 ml koncentrat za rastvor za infuziju

novartis ba d.o.o. - gemcitabin - koncentrat za rastvor za infuziju - 10 mg/1 ml - 20 ml koncentrata za rastvor za infuziju sadrži: 200 mg gemcitabina (u obliku gemcitabinhidrohlorida)